GeorgeJHannaMD(He/Him)
Infectious Disease • Princeton, NJHIV/AIDS Medicine
Independent Biopharmaceutical Consultant with Expertise in Clinical Drug Development, Scientific and Medical Affairs, and Infectious Diseases
Dr. Hanna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1805 Stuart Rd W
Princeton, NJ 08540
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1996 - 2000
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
Baylor College of MedicineClass of 1992
Certifications & Licensure
PA State Medical License 2001 - 2026
NJ State Medical License 2009 - 2025
IL State Medical License 2005 - 2008
MA State Medical License 1995 - 2003- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects Start of enrollment: 1997 Nov 01
Publications & Presentations
PubMed
- 1 citationsTime to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.Russell L Rothman, Thomas G Stewart, Ahmad Mourad, David R Boulware, Matthew W McCarthy
JAMA Network Open. 2024-10-01 - 12 citationsHigher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.Thomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, Christopher J Lindsell, David R Boulware
JAMA. 2023-12-26 - 3 citationsThe Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19.Nalini Ambrose, Alpesh Amin, Brian Anderson, Monica Bertagnolli, Francis Campion
Journal of General Internal Medicine. 2023-12-01
Press Mentions
Merck’s Pifeltro (Doravirine) and Delstrigo (doravirine/lamivudine/tenofovir Disoproxil Fumarate) Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically SuppressedSeptember 24th, 2019
FDA Approves Expanded Indications for 2 HIV TherapiesSeptember 20th, 2019
Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019July 24th, 2019- Join now to see all
Grant Support
- Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases2001
- Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases1999–2001
Professional Memberships
- Member
- Member
External Links
- LinkedInhttps://www.linkedin.com/in/george-hanna-35221924/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
